This report investigates the Rare Disease Pipeline Analysis Landscape in 2023 in the pharmaceutical industry from the standpoint of drug development. It provides a high-level analysis of key trends and movements within the industry via regulatory, clinical, and market-based analysis, allowing you to discern the large-scale changes and how best to pivot to prioritize these trends within your sector.
Scope
This 29-page report gives important, expert insight you won’t find in any other source. 12 figures throughout the report illustrate major points and trends in Rare Disease. This report is required reading for:
- Investors that want to understand current rare disease trends impacting the biopharmaceutical industry as well as identifying companies to invest in
- Companies that are interested in seeing the extent and impact of rare diseases trends and how best to pivot towards it.
- Large pharma companies with investment groups or BD teams looking to see which rare disease led biopharmaceutical companies lead the industry currently and what their focuses are on
Reasons to Buy
- Insights on Drug Development Landscape
- Insights on Leading key companies and sponsors
- Insights on Upcoming drug launches
- Insights on Innovation Landscape
- Insights on Patent grant trends
- Insights on Leading companies by patents
- Insights on Dealmaking trends
- Insights on Orphan drug designation approvals over time
Table of Contents
- Rare Disease Overview
- Regulatory Reforms
- Drug Development Landscape
- Drugs by therapy area
- Drugs by indication
- Therapy area sales growth
- Leading key companies and sponsors
- Upcoming drug launches
- Innovation Landscape
- Patent grant trends
- Leading companies by patents
- Dealmaking trends
- Orphan drug designation approvals over time
- AI Industry Trends
- Most Active Companies in AI Development
- Therapy Areas by Deal Value and Volume
- Key Findings
- Appendix
- Abbreviations
- Methodology
- Related Reports
- About the Authors
- About the Publisher
- Contact the Publisher
- Therapy Area by Pipeline Drugs 2023
- Indications by Pipeline Drugs
- Therapy Area Forecast Annual Sales Growth (2023 to 2029)
- Drugs by Highest Development Stage
- Leading Companies by Drugs in Late-Stage Development
- Top Clinical Trial Sponsors in 2024
- Top 10 Drug Launches by Sales
- Rare Disease Patents Granted Over Time (2018 to 2022)
- Leading Patent Assignees (2016 to 2022)
- Rare Disease Deals Over Time (2013 to 2022)
- Deals by Therapy Area (2018 to 2022)
- Orphan Drug Designation Approvals Over Time (2013 to 2022)
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Pfizer
- Merck & Co
- Alexion Pharmaceuticals
- Bristol Myers Squibb
- Ionis Pharmaceuticals
- Regeneron Pharmaceuticals
- Novartis AG
- Amgen Inc
- Boehringer Ingelheim International GmbH
- Sarepta Therapeutics
- Anavex Life Science Corp
- AstraZeneca
- Johnson & Johnson
- AbbVie
- GSK
- F.hoffman-la Roche
- Vertex Pharmaceuticals
- Alaunos Therapeutics
- Argenx Inc
- BridgeBio Pharma
